Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 187,675	$ 154,901
Marketable securities	284,255	236,949
Accounts receivable, net of reserves of $4,576 in 2017 and $4,523 in 2016	234,597	204,494
Inventories	164,318	158,034
Other current assets	101,140	91,206
Total current assets	971,985	845,584
Long-Term Assets:
Property and equipment, net	379,096	357,422
Goodwill	199,873	178,228
Intangible assets, net	43,846	46,155
Other long-term assets	118,616	103,315
Total long-term assets	741,431	685,120
TOTAL ASSETS	1,713,416	1,530,704
Current Liabilities:
Accounts payable	66,968	60,057
Accrued liabilities	253,418	236,131
Line of credit	655,000	611,000
Current portion of deferred revenue	29,181	27,380
Total current liabilities	1,004,567	934,568
Long-Term Liabilities:
Deferred income tax liabilities	25,353	39,287
Long-term debt	606,075	593,110
Long-term deferred revenue, net of current portion	35,545	33,015
Other long-term liabilities	95,718	38,937
Total long-term liabilities	762,691	704,349
Total liabilities	1,767,258	1,638,917
Commitments and Contingencies (Note 14)
Stockholders’ Equity (Deficit):
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 104,275 shares in 2017 and 103,341 shares in 2016	10,428	10,334
Additional paid-in capital	1,073,931	1,011,895
Deferred stock units: Outstanding: 229 units in 2017 and 231 units in 2016	5,988	5,514
Retained earnings	803,545	540,401
Accumulated other comprehensive loss	(36,470)	(43,053)
Treasury stock, at cost: 17,171 shares in 2017 and 15,367 shares in 2016	(1,911,528)	(1,633,443)
Total IDEXX Laboratories, Inc. stockholders’ equity (deficit)	(54,106)	(108,352)
Noncontrolling interest	264	139
Total stockholders’ equity (deficit)	(53,842)	(108,213)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 1,713,416	$ 1,530,704